Hemant Surgical Industries
Close ·
Key Fundamentals
SMEHealthcare Equipment & SuppliesHealthcarePrice-based figures at the close · TTM
- ROCE
- 18.90%
- Debt to Equity
- 0.36
- EPS (TTM)
- —
- Book Value
- ₹107.89
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 5.64
- ROE
- 16.90%
- Dividend Yield
- 0.00%
- EBITDA
- ₹29.10 Cr
- 52W High
- ₹679.00
- 52W Low
- ₹215.00
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 84/100
Category scores
- Quality
- 71
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 21
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 99
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 46
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 96
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 40
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company has delivered good profit growth of 65.6% CAGR over last 5 years
- Company's working capital requirements have reduced from 45.5 days to 24.0 days
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 83.7 to 106 days.
- Promoter holding has decreased over last 3 years: -20.7%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 3 | 5 | 11 |
| Oscillators | Bearish | 3 | 5 | 1 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 58.22
- Neutral
- MACD (12,26,9)
- 12.29
- Bearish
- SMA (50)
- 526.23
- Bullish
- SMA (200)
- 377.17
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | +30.95% |
|---|---|
| 3Y | +28.45% |
| 1Y | +115.89% |
Net profit
| 5Y | +78.26% |
|---|---|
| 3Y | +31.04% |
| 1Y | +125.00% |
Operating cash flow
| 5Y | Outflow widened by ₹28 Cr |
|---|---|
| 3Y | Turned negative |
| 1Y | Turned negative |
Operating margin· change in pp
| 5Y | +4.96 pp |
|---|---|
| 3Y | −0.13 pp |
| 1Y | +1.55 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2018 | ₹51.00 Cr |
|---|---|
| Mar 2019 | ₹56.00 Cr |
| Mar 2020 | ₹56.00 Cr |
| Mar 2021 | ₹60.00 Cr |
| Mar 2022 | ₹101 Cr |
| Mar 2023 | ₹109 Cr |
| Mar 2024 | ₹106 Cr |
| Mar 2025 | ₹107 Cr |
| Mar 2026 | ₹231 Cr |
Net profit by year
| Mar 2018 | ₹1.00 Cr |
|---|---|
| Mar 2019 | ₹1.00 Cr |
| Mar 2020 | ₹0.00 Cr |
| Mar 2021 | ₹1.00 Cr |
| Mar 2022 | ₹5.00 Cr |
| Mar 2023 | ₹8.00 Cr |
| Mar 2024 | ₹10.00 Cr |
| Mar 2025 | ₹8.00 Cr |
| Mar 2026 | ₹18.00 Cr |
Half-yearly Results
₹ Cr| Particulars | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 58 | 48 | 58 | 49 | 58 | 64 | 167 |
| Expenses | 47 | 52 | 44 | 51 | 45 | 52 | 57 | 151 |
| Operating Profit | 4 | 6 | 3 | 7 | 4 | 6 | 8 | 16 |
| OPM % | 8% | 11% | 7% | 13% | 7% | 10% | 12% | 9% |
| Other Income | 1 | 1 | 3 | 2 | 2 | 3 | 2 | 3 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBT | 4 | 6 | 5 | 8 | 4 | 6 | 7 | 16 |
| Tax % | 36% | 18% | 17% | 27% | 29% | 18% | 25% | 22% |
| Net Profit | 2 | 5 | 4 | 6 | 3 | 5 | 5 | 13 |
| EPS (₹) | 2.89 | 6.93 | 3.75 | 5.63 | 3.05 | 4.74 | 4.15 | 9.84 |
Profit & Loss
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 56 | 56 | 60 | 101 | 109 | 106 | 107 | 231 |
| Expenses | 48 | 53 | 53 | 57 | 95 | 98 | 95 | 97 | 208 |
| Operating Profit | 2 | 3 | 3 | 3 | 6 | 11 | 10 | 9 | 23 |
| OPM % | 4.9% | 4.8% | 4.7% | 5% | 6% | 10% | 10% | 9% | 10% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 5 | 6 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 4 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| PBT | 1 | 1 | 1 | 1 | 6 | 10 | 13 | 11 | 24 |
| Tax % | 10% | 8% | 41% | 9% | 25% | 24% | 23% | 23% | 23% |
| Net Profit | 1 | 1 | 0 | 1 | 5 | 8 | 10 | 8 | 18 |
| EPS (₹) | 3.13 | 3.77 | 1.67 | 4.53 | 15.37 | 9.95 | 9.39 | 7.79 | 13.98 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 8 | 10 | 10 | 13 |
| Reserves | 5 | 6 | 5 | 8 | 11 | 16 | 44 | 53 | 124 |
| Borrowings | 9 | 11 | 14 | 14 | 10 | 7 | 7 | 31 | 50 |
| Other Liabilities | 12 | 14 | 23 | 15 | 32 | 34 | 38 | 54 | 87 |
| Total Liabilities | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 274 |
| Fixed Assets | 7 | 8 | 10 | 11 | 12 | 13 | 18 | 40 | 53 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 |
| Investments | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 0 | 0 |
| Other Assets | 21 | 25 | 33 | 29 | 42 | 51 | 77 | 96 | 220 |
| Total Assets | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 274 |
Cash Flow
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 2 | −4 | 12 | 6 | −4 | 5 | −32 |
| Investing | 0 | 0 | −2 | −2 | 0 | −3 | −12 | −30 | −10 |
| Financing | 0 | 0 | 2 | 5 | −8 | −1 | 21 | 22 | 76 |
| Net Cash Flow | 0 | 0 | 2 | −2 | 4 | 3 | 5 | −4 | 34 |
| Free Cash Flow | 0 | 0 | −1 | −7 | 12 | 2 | −13 | −31 | −37 |
| CFO/EBITDA | 0 | 0 | 68 | −127 | 197 | 84 | −9 | 78 | −118 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 36 | 35 | 26 | 56 | 58 | 75 | 70 | 106 |
| Inventory Days | 64 | 73 | 125 | 113 | 57 | 67 | 99 | 206 | 120 |
| Days Payable | 102 | 97 | 143 | 89 | 92 | 110 | 116 | 188 | 146 |
| Cash Conversion Cycle | −3 | 12 | 17 | 51 | 21 | 15 | 58 | 87 | 80 |
| Working Capital Days | 12 | 23 | −28 | 41 | −19 | 2 | 52 | 61 | 24 |
| ROCE % | — | 15% | 12% | 14% | 32% | 45% | 30% | 16% | 19% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Hemant Surgical Industries insights
55 extracted metrics across FY18–FY26.
Documents
- 9 Apr 2026
- 10 Apr 2025
- 22 Jan 2025
- 15 Oct 2024
- 30 Aug 2024
- General announcements 7 Oct 2026
Frequently Asked Questions about Hemant Surgical Industries
What does Hemant Surgical Industries Ltd do?
Where is Hemant Surgical Industries Ltd (HSIL) listed?
Which sector does Hemant Surgical Industries Ltd belong to?
What is the 52-week high and low of Hemant Surgical Industries Ltd?
What is the Return on Equity (ROE) of Hemant Surgical Industries Ltd?
Company Information
Incorporated in 1989, Hemant Surgical Industries Ltd is in the business of Medical Equipment & Supplies
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543916.md for Hemant Surgical Industries Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.